Loading…

Laboratory confirmation of congenital rubella syndrome in South Korea in 2017: A genomic epidemiological investigation

•Endemic rubella has been eliminated in South Korea since 2011.•A case of suspected congenital rubella syndrome (CRS) was reported in 2017.•CRS was confirmed via rubella-specific IgM and RNA in urine and a throat swab.•Rubella virus, genotype 2b of Vietnamese origin was isolated in a throat swab.•La...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2020-10, Vol.38 (44), p.6868-6871
Main Authors: Wang, Jin-Sook, Lee, Hye Min, Kim, Su Jin, Kim, Jun-Sub, Kang, Chun, won Jung, Chae, In, Hye kyung, Seo, Dong Hee, Lee, Dong Han, Chung, Yoon-Seok
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Endemic rubella has been eliminated in South Korea since 2011.•A case of suspected congenital rubella syndrome (CRS) was reported in 2017.•CRS was confirmed via rubella-specific IgM and RNA in urine and a throat swab.•Rubella virus, genotype 2b of Vietnamese origin was isolated in a throat swab.•Laboratory surveillance is critical to rubella elimination. The WHO Regional Verification Commission certified in 2017 that Korea was the first country in the WHO Western Pacific Region to achieve rubella elimination. A suspected congenital rubella syndrome (CRS) was reported to the Korea Centers for Disease Control and Prevention in August 2017. The mother of a new-born had visited Vietnam during her pregnancy. CRS was confirmed based on the detection of rubella-specific IgM and rubella RNA in the urine and throat swab. Rubella virus isolated from the throat swab was classified as genotype 2B, and a phylogenetic analysis indicated that this genotype had been imported from Vietnam. This is the first report of CRS confirmed using virus isolation in Korea. Laboratory surveillance plays a critical role in the elimination of rubella through the provision of laboratory testing data, and characterisation of circulating strains.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2020.08.064